글로벌 만성 과립종성 질환 치료 시장 – 2028년까지의 산업 동향 및 예측

시장 분석 및 통찰력: 글로벌 만성 과립종증 치료 시장

만성 과립종성 질환 치료 시장은 2021년부터 2028년까지의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 시장이 2021년부터 2028년까지의 예측 기간 동안 4.7%의 CAGR로 성장하고 있다고 분석합니다.

만성 과립종성 질환 또는 CGD는 백혈구(식세포)가 특정 유형의 박테리아 와 진균을 죽일 수 없는 일종의 질환입니다. 기본적으로 식세포 백혈구에서 호흡 폭발을 초래하는 NADPH 산화효소 복합체의 결함으로 인해 발생하는 유전성 원발성 면역 결핍 질환입니다. 환자는 피부 감염, 림프절 감염, 폐렴, 폐 감염, 간 감염, 위장 염증 또는 기타 감염을 겪을 수 있습니다.

생활 방식의 변화와 식습관의 변화와 같은 요인은 예측 기간 내에 만성 과립종성 질환 치료 시장의 전반적인 성장을 더욱 가속화할 것으로 예상됩니다. 또한 일부 개발도상국에서 희귀 질환의 유병률이 증가하고 연구 개발 활동이 증가함에 따라 전반적인 시장 수요가 증가합니다. 그러나 만성 과립종성 질환의 치료 및 진단 검사 와 관련된 높은 비용과 같은 다양한 유형의 만성 과립종성 질환에 대한 효과적인 치료법이 부족하여 향후 몇 년 동안 만성 과립종성 질환 치료 시장 성장을 방해할 가능성이 가장 높습니다.

또한, 기술의 발전과 의료 부문에 대한 정부 자금 지원 증가는 가까운 미래에 만성 과립종증 치료 시장 성장에 적합한 기회를 더욱 확대할 것입니다. 그러나 개발도상국과 저개발 경제권에서 이 질병에 대한 인식 부족은 예측 기간 동안 어려운 요인 중 하나가 될 수 있습니다.

This chronic granulomatous disease treatment market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on chronic granulomatous disease treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth. 

Global Chronic Granulomatous Disease Treatment Market Scope and Market Size

The chronic granulomatous disease treatment market is segmented on the basis of type, diagnosis, treatment, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications. 

• On the basis of type, the chronic granulomatous disease treatment market is segmented into x-linked chronic granulomatous disease and autosomal recessive chronic granulomatous disease.
• On the basis of diagnosis, the market is segmented into neutrophil function tests, genetic testing, prenatal testing and others.
• On the basis of treatment, the market is segmented into infection management, interferon-gamma, stem cell transplantation, medication, bone marrow transplant, gene therapy and others.
• On the basis of route of administration, the market is segmented into oral, injectable and others.
• On the basis of end- users, the market is segmented into hospitals, homecare, specialty clinics and others.
• On the basis of distribution channel, the market is segmented into hospital pharmacy, online pharmacy, retail pharmacy and others.

Chronic Granulomatous Disease Treatment Market Country Level Analysis

The chronic granulomatous disease treatment market is analyzed and market size insights and trends are provided by type, diagnosis, treatment, route of administration, end-users and distribution channel as referenced above.

The countries covered in the chronic granulomatous disease treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the chronic granulomatous disease treatment market owing to the presence of well-developed healthcare infrastructure, a well-developed healthcare sector, growing occurrence of chronic granulomatous disease (CGD) and relatively large number of research and development activities within the region. Asia Pacific, on the other hand, is projected to observe significant amount of growth in the chronic granulomatous disease treatment market because the increasing government funding for the healthcare sector and increasing research and development activities.

The country section of the chronic granulomatous disease treatment market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Chronic Granulomatous Disease Treatment Market Share Analysis

The chronic granulomatous disease treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to chronic granulomatous disease treatment market.

만성 과립종성 질환 치료 시장 보고서에 포함된 주요 기업은 Clinigen Group plc, Orchard Therapeutics plc, Généthon, Horizon Therapeutics plc, ViroMed. Co.Ltd, Bellicum Pharmaceuticals, Inc., Pfizer Inc., F. Hoffmann-La Roche Ltd, Novartis AG, Lonza, GlaxoSmithKline plc., Eli Lilly and Company, Johnson & Johnson Services, Inc., Merck KGaA, Smith & Nephew, JCR Pharmaceuticals Co.Ltd, MaxCyte, Inc., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Antares Pharma 등 국내 및 글로벌 기업입니다. 시장 점유율 데이터는 글로벌, 북미, 유럽, 아시아 태평양(APAC), 중동 및 아프리카(MEA), 남미에 대해 개별적으로 제공됩니다. DBMR 분석가는 경쟁 우위를 이해하고 각 경쟁자에 대한 경쟁 분석을 개별적으로 제공합니다.

SKU-50381